JP2014533680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533680A5 JP2014533680A5 JP2014541761A JP2014541761A JP2014533680A5 JP 2014533680 A5 JP2014533680 A5 JP 2014533680A5 JP 2014541761 A JP2014541761 A JP 2014541761A JP 2014541761 A JP2014541761 A JP 2014541761A JP 2014533680 A5 JP2014533680 A5 JP 2014533680A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- medicament
- diabetes
- thcv
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 17
- 239000003472 antidiabetic agent Substances 0.000 claims 4
- 229940125708 antidiabetic agent Drugs 0.000 claims 3
- 210000004153 islets of langerhan Anatomy 0.000 claims 3
- 241000218236 Cannabis Species 0.000 claims 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 2
- 229950011318 cannabidiol Drugs 0.000 claims 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 2
- 229960004242 dronabinol Drugs 0.000 claims 2
- 208000004104 gestational diabetes Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 238000002636 symptomatic treatment Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical group OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1120066.4 | 2011-11-21 | ||
| GB1120066.4A GB2496687A (en) | 2011-11-21 | 2011-11-21 | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
| PCT/GB2012/052869 WO2013076471A1 (en) | 2011-11-21 | 2012-11-20 | Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533680A JP2014533680A (ja) | 2014-12-15 |
| JP2014533680A5 true JP2014533680A5 (cg-RX-API-DMAC10.html) | 2016-01-14 |
| JP6338531B2 JP6338531B2 (ja) | 2018-06-06 |
Family
ID=45475480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541761A Active JP6338531B2 (ja) | 2011-11-21 | 2012-11-20 | 膵島細胞の保護に使用するためのテトラヒドロカンナビバリン（ｔｈｃｖ） |
Country Status (14)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US10774288B2 (en) | 2013-09-18 | 2020-09-15 | The Werc Shop, LLC | Terpene-based compositions, processes, methodologies for creation and products thereby |
| US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| JP7067793B2 (ja) | 2015-10-23 | 2022-05-16 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基編集因子およびその使用 |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| IL264565B2 (en) | 2016-08-03 | 2024-07-01 | Harvard College | Adenosine nucleobase editors and uses thereof |
| EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
| SG11201908658TA (en) | 2017-03-23 | 2019-10-30 | Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN110575447B (zh) * | 2018-06-07 | 2022-11-29 | 汉义生物科技（北京）有限公司 | 一种用于防治糖尿病的药物组合物及其用途 |
| WO2019232740A1 (zh) * | 2018-06-07 | 2019-12-12 | 汉义生物科技（北京）有限公司 | 一种用于防治糖尿病的药物组合物及其用途 |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020030843A2 (es) * | 2018-08-10 | 2020-02-13 | Servicio Andaluz De Salud | Agentes para el tratamiento del trastorno por uso de alcohol |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US20210400894A1 (en) * | 2018-11-09 | 2021-12-30 | Agriculture Victoria Services Pty Ltd | Plants with a Cannabinoid Profile Enriched for Cannabidiol |
| WO2020191246A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| EP4188363A4 (en) | 2020-07-28 | 2024-10-16 | Wsmef, Llc | FULL-SPECTRUM HEMP OIL MICELLE PREPARATIONS FOR THE TREATMENT OF TYPE II DIABETES, REDUCING INFLAMMATION DURING COVID-19 AND IMPROVING SLEEP QUALITY |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| CN113135885A (zh) * | 2021-04-07 | 2021-07-20 | 上海同田生物技术有限公司 | 一种高速逆流色谱分离纯化四氢次大麻酚的方法 |
| US12011470B2 (en) | 2021-07-28 | 2024-06-18 | Clint Sorensen | Micelle preparations of full-spectrum hemp oil |
| WO2024006896A1 (en) * | 2022-06-29 | 2024-01-04 | The Regents Of The University Of California | Uses of hydrogenated cannabidiol (h4cbd) and advanced metabolic syndrome |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160420A0 (en) | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
| GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| CA2586358C (en) * | 2004-11-16 | 2015-11-24 | Gw Pharma Limited | Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor |
| US20070060639A1 (en) * | 2005-09-09 | 2007-03-15 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| JP5072848B2 (ja) * | 2005-09-20 | 2012-11-14 | ノバルティス アーゲー | 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用 |
| GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| GB2459637B (en) * | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
-
2011
- 2011-11-21 GB GB1120066.4A patent/GB2496687A/en not_active Withdrawn
-
2012
- 2012-11-20 GB GB1220874.0A patent/GB2496761A/en not_active Withdrawn
- 2012-11-20 CN CN201280057131.2A patent/CN103945841A/zh active Pending
- 2012-11-20 JP JP2014541761A patent/JP6338531B2/ja active Active
- 2012-11-20 AU AU2013201809A patent/AU2013201809B2/en not_active Ceased
- 2012-11-20 EP EP12795839.5A patent/EP2782568B1/en active Active
- 2012-11-20 PT PT127958395T patent/PT2782568E/pt unknown
- 2012-11-20 WO PCT/GB2012/052869 patent/WO2013076471A1/en not_active Ceased
- 2012-11-20 DK DK12795839.5T patent/DK2782568T3/en active
- 2012-11-20 ES ES15185536T patent/ES2714350T3/es active Active
- 2012-11-20 EP EP15185536.8A patent/EP3028697B1/en active Active
- 2012-11-20 ES ES12795839.5T patent/ES2560835T3/es active Active
- 2012-11-20 PL PL12795839T patent/PL2782568T3/pl unknown
- 2012-11-20 BR BR112014012159A patent/BR112014012159A2/pt not_active IP Right Cessation
- 2012-11-20 CA CA 2856102 patent/CA2856102A1/en not_active Abandoned
- 2012-11-20 MX MX2014006057A patent/MX348564B/es active IP Right Grant
-
2014
- 2014-05-16 US US14/358,861 patent/US20160243075A2/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533680A5 (cg-RX-API-DMAC10.html) | ||
| JP2011509989A5 (cg-RX-API-DMAC10.html) | ||
| EA021275B9 (ru) | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания | |
| NZ608829A (en) | Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof | |
| NZ710575A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| WO2012125830A3 (en) | Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control | |
| BR112013004756B1 (pt) | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| MX2013008484A (es) | Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2. | |
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| MX336657B (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| JP2014518860A5 (cg-RX-API-DMAC10.html) | ||
| JP2015514797A5 (cg-RX-API-DMAC10.html) | ||
| RU2014145931A (ru) | Композиция для лечения нарушений метаболизма | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| MX387086B (es) | Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas | |
| JP2012517449A5 (cg-RX-API-DMAC10.html) | ||
| PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| UA112352C2 (uk) | Фармацевтична композиція для профілактики і лікування психічних, поведінкових, когнітивних розладів | |
| JP2018503644A5 (cg-RX-API-DMAC10.html) | ||
| CL2012000797A1 (es) | Compuestos derivados de pirazol, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad o condicion tal como sindrome metabolico, diabetes, resistencia a la insulina, complicaciones diabeticas y trastornos del peso corporal. | |
| PH12015500653A1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| JP2012525422A5 (cg-RX-API-DMAC10.html) |